Rowse Phillip G, Roden Anja C, Corl Frank M, Allen Mark S, Cassivi Stephen D, Nichols Francis C, Shen K Robert, Wigle Dennis A, Blackmon Shanda H
1 Division of General Thoracic Surgery, 2 Department of Laboratory Medicine and Pathology, 3 Department of Medical Illustration/Animation, Mayo Clinic, Rochester, MN, USA.
Ann Cardiothorac Surg. 2015 Nov;4(6):519-26. doi: 10.3978/j.issn.2225-319X.2015.07.03.
The prevalence of minimally invasive thymectomy (MIT) is increasing and may have significant benefit to patients in terms of morbidity and post-operative recovery. Our aim was to review the Mayo Clinic experience of MIT.
We reviewed data from all MIT cases collected in a prospectively maintained database from January 1995 to February 2015. Data were collected regarding patient demographics, perioperative management and patient outcomes.
A total of 510 thymectomies were performed in 20 years. Fifty-six patients underwent MIT (45 video-assisted thoracoscopy, 11 robotic-assisted). The median age was 55 years (range, 23-87 years) with male to female ratio of 25:31. Thymoma was the main pathologic diagnosis in 27/56 patients (48%), with 11/27 (41%) associated with myasthenia gravis (MG), and 16/27 (59%) non-MG. Other pathologies included 1/56 (2%) of each teratoma, lymphoma, lymphangioma, carcinoma and thymolipoma. There were 3/56 (5%) atrophic glands, 4/56 (7%) cysts, 6/56 (11%) benign glands and 11/56 (20%) hyperplastic. Mean blood loss (mL) and operative time (min) were significantly lower in the video-assisted thoracoscopic surgery (VATS) group compared to robotic (65±41 vs. 160±205 mL, P=0.04 and 102±39 vs. 178±53 min, P=0.001, respectively). There was no 30-day mortality. Post-operative morbidity occurred in 7/45 (16%) VATS patients (phrenic nerve palsy 7%, pericarditis 4%, atrial fibrillation 2%, pleural effusion 2%) and 1/11 (9%) robotic (urinary retention requiring self-catheterization). Reoperation was required in 1/3 of VATS patients with phrenic nerve palsy. There was no significant difference in length of hospital stay [VATS 1.5 days (range, 1-4 days) and robotic 2 days (range, 1-5 days) VATS; P=0.05]. Mean follow-up was 18.4 months (range, 1-50.4 months) with no tumor recurrences.
MIT can be performed with low morbidity and mortality. VATS is associated with reduced blood loss, operative times and earlier hospital discharge compared to robotic MIT.
微创胸腺切除术(MIT)的普及率正在上升,在发病率和术后恢复方面可能对患者有显著益处。我们的目的是回顾梅奥诊所的MIT经验。
我们回顾了1995年1月至2015年2月前瞻性维护数据库中收集的所有MIT病例的数据。收集了患者人口统计学、围手术期管理和患者结局的数据。
20年共进行了510例胸腺切除术。56例患者接受了MIT(45例电视辅助胸腔镜手术,11例机器人辅助手术)。中位年龄为55岁(范围23 - 87岁),男女比例为25:31。胸腺瘤是27/56例患者(48%)的主要病理诊断,其中11/27例(41%)与重症肌无力(MG)相关,16/27例(59%)与非MG相关。其他病理包括畸胎瘤、淋巴瘤、淋巴管瘤、癌和胸腺脂肪瘤各1/56例(2%)。有3/56例(5%)萎缩性腺,4/56例(7%)囊肿,6/56例(11%)良性腺,11/56例(20%)增生。电视辅助胸腔镜手术(VATS)组的平均失血量(mL)和手术时间(min)显著低于机器人辅助组(分别为65±41 vs. 160±205 mL,P = 0.04;102±39 vs. 178±53 min,P = 0.001)。无30天死亡率。7/45例(16%)VATS患者发生术后并发症(膈神经麻痹7%,心包炎4%,心房颤动2%,胸腔积液2%),1/11例(9%)机器人辅助手术患者发生术后并发症(需要自行导尿的尿潴留)。1/3膈神经麻痹的VATS患者需要再次手术。住院时间无显著差异[VATS组1.5天(范围1 - 4天),机器人辅助组2天(范围1 - 5天);P = 0.05]。平均随访18.4个月(范围1 - 50.个月),无肿瘤复发。
MIT可以在低发病率和死亡率的情况下进行。与机器人辅助MIT相比,VATS与失血量减少、手术时间缩短和更早出院相关。